SCM
CNTA

Silverarc Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Silverarc Capital Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.5M Buy
466,345
+8,142
+2% +$208K 1.89% 18
2025
Q4 		$11.5M Buy
458,203
+316,965
+224% +$8.03M 1.59% 20
2025
Q3 		$3.43M Buy
141,238
+136,238
+2,725% +$2.42M 0.46% 52
2025
Q2 		$65.7K Sell
5,000
-227,758
-98% -$2.89M 0.01% 63
2025
Q1 		$3.35M Sell
232,758
-366,194
-61% -$5.99M 0.68% 39
2024
Q4 		$10M Sell
598,952
-145,640
-20% -$2.41M 2.19% 14
2024
Q3 		$11.9M Buy
+744,592
New +$9.12M 2.67% 11

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Silverarc Capital Management's CNTA Position: Q1 2026 in Review

Silverarc Capital Management increased its Centessa Pharmaceuticals (CNTA) stake by 1.8% in Q1 2026, buying an estimated $208K and bringing the position to 466,345 shares worth $18.5M. The position accounts for 1.89% of the portfolio, ranked #18.

Silverarc Capital Management first reported a position in CNTA in Q3 2024 and has held it in 7 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Silverarc Capital Management held 466,345 shares of Centessa Pharmaceuticals worth $18.5M as of Q1 2026.
  • Silverarc Capital Management bought 8,142 Centessa Pharmaceuticals shares in Q1 2026, an estimated $208K.
  • Centessa Pharmaceuticals made up 1.89% of Silverarc Capital Management's portfolio in Q1 2026, its #18 holding.
  • Silverarc Capital Management first reported a position in Centessa Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.